Solventum (NYSE:SOLV) Hits New 1-Year High – What’s Next?

Solventum Corporation (NYSE:SOLV)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $88.24 and last traded at $88.2450, with a volume of 667273 shares trading hands. The stock had previously closed at $86.17.

Analyst Upgrades and Downgrades

SOLV has been the topic of several research reports. UBS Group upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $95.00 target price on the stock in a report on Tuesday. Stifel Nicolaus dropped their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. BMO Capital Markets initiated coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $91.00 price objective on shares of Solventum in a report on Monday, July 13th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $86.00.

Solventum Trading Up 2.3%

The stock’s 50 day moving average is $77.78 and its two-hundred day moving average is $74.17. The company has a market capitalization of $15.26 billion, a PE ratio of 10.80, a price-to-earnings-growth ratio of 1.24 and a beta of 0.66. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Solventum

Institutional investors have recently bought and sold shares of the business. CrossGen Wealth LLC purchased a new position in shares of Solventum during the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Solventum during the 3rd quarter valued at approximately $25,000. Clearstead Trust LLC raised its position in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after purchasing an additional 150 shares during the last quarter. JNBA Financial Advisors raised its holdings in shares of Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new position in Solventum in the 2nd quarter valued at $28,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.